In the United States, cancer is the most common cause of deathamong people under the age of 85 years, and colorectal canceris the second most common cause of death from cancer.1 Chemotherapyfor colorectal cancer has until recently typically consistedof the empirical use of cytotoxic agents guided by the resultsof controlled clinical trials. Cancer therapy has now entereda new era, however, owing to remarkable advances in our understandingof the nature of molecular and biochemical events involved inthe process of carcinogenesis and tumor growth. Biologicallytargeted therapies are now commonly used as part of . . . [Full Text of this Article]
Source Information
From the Division of Medical Oncology, Gastrointestinal Medical Oncology Program, University of Colorado Cancer Center, Aurora (W.A.M.); and the Denver Department of Veterans Affairs Medical Center and the University of Colorado Denver School of Medicine, Denver (D.J.A.).
This article has been cited by other articles:
Simon, R. M., Paik, S., Hayes, D. F.
(2009). Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. JNCI J Natl Cancer Inst
101: 1446-1452
[Abstract][Full Text]
Nevo, J., Mattila, E., Pellinen, T., Yamamoto, D. L., Sara, H., Iljin, K., Kallioniemi, O., Bono, P., Heikkila, P., Joensuu, H., Warri, A., Ivaska, J.
(2009). Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. Clin. Cancer Res.
15: 6570-6581
[Abstract][Full Text]
Yen, L.-C., Yeh, Y.-S., Chen, C.-W., Wang, H.-M., Tsai, H.-L., Lu, C.-Y., Chang, Y.-T., Chu, K.-S., Lin, S.-R., Wang, J.-Y.
(2009). Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res.
15: 4508-4513
[Abstract][Full Text]
Previous
